Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
Researchers observed a bidirectional, causal relationship between gut microbiome and schizophrenia in a Mendelian randomization analysis.
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...
Many researchers believe that schizophrenia can affect a person's ability to smell and how they perceive smells. However, the ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
Researchers identified that impaired corollary discharge (CD) and noisy efference copy (EC) in schizophrenia disrupt ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
A recent study has suggested having a cat could potentially double a person's risk of developing schizophrenia-related disorders. Australian researchers conducted an analysis of 17 studies published ...